KAYLA SMITH: Open Payments
NPI 1457132870 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,457 in 83 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,587 · 2025 $1,457
Food & beverage: $1,457
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 25 | $396 |
| Bayer Healthcare Pharmaceuticals Inc. | 16 | $229 |
| Travere Therapeutics, Inc. | 9 | $177 |
| Otsuka America Pharmaceutical, Inc. | 9 | $151 |
| Vifor Pharma, Inc. | 5 | $95 |
| Amgen Inc. | 4 | $86 |
| Novartis Pharmaceuticals Corporation | 5 | $85 |
| Apellis Pharmaceuticals, Inc. | 2 | $65 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
Products named: TARPEYO, Kerendia, JYNARQUE, Veltassa, KRYSTEXXA, Fabhalta, BENLYSTA, FARXIGA.
Industry payments across PA — which companies pay providers there.
